timeline

@moatrx • one week ago • comments: 0

Posted a new blog:
GCC SPINAL MUSCULAR ATROPHY LAUNCH READINESS

Three NPHC-covered SMA agents already span GCC Types 1 to 3, leaving a new entrant exactly two open niches to target. Zolgensma (onasemnogene abeparvovec) is...

@moatrx • one week ago • comments: 0

Posted a new blog:
US SICKLE CELL DISEASE LAUNCH READINESS

Two drug withdrawals opened a 55,000 to 65,000-patient white space in US sickle cell disease that speed, not differentiation, now decides. Hydroxyurea, generic and...

@moatrx • one week ago • comments: 0

Posted a new blog:
UK SICKLE CELL DISEASE LAUNCH READINESS

NICE rejected crizanlizumab on cost grounds even with a discount, setting a hard WAC ceiling for the next UK sickle cell entrant. Hydroxycarbamide remains NHS...

@moatrx • one week ago • comments: 0

Posted a new blog:
GCC SICKLE CELL DISEASE LAUNCH READINESS

GCC sickle cell disease affects 200,000 to 250,000 patients, yet zero novel SFDA-registered therapy exists since crizanlizumab's 2023 withdrawal. Hydroxyurea is...

@moatrx • one week ago • comments: 0

Posted a new blog:
US POMPE DISEASE LAUNCH READINESS

375 to 600 US late-onset Pompe patients are failing next-gen ERT, and ADA superiority decides who can reach them. Nexviazyme (avalglucosidase alfa, Sanofi,...

@moatrx • one week ago • comments: 0

Posted a new blog:
UK POMPE DISEASE LAUNCH READINESS

An ADA-positive-specific NICE case for late-onset Pompe clears far more directly than competing on incremental FVC improvement against alglucosidase. Alglucosidase...

@moatrx • one week ago • comments: 0

Posted a new blog:
GCC POMPE DISEASE LAUNCH READINESS

Sanofi already controls both the incumbent Pompe molecule and the KFSH&RC home-infusion relationship a new ERT entrant must replicate from scratch....

@moatrx • one week ago • comments: 0

Posted a new blog:
US PNH LAUNCH READINESS

A new PNH agent must beat iptacopan's oral bar in the EVH-anaemia cohort that anti-C5 blockade cannot resolve, within iptacopan's own pricing ceiling. Ravulizumab...

@moatrx • one week ago • comments: 0

Posted a new blog:
UK PNH LAUNCH READINESS

Both approved PNH complement inhibitors cleared NICE's standard £20,000 to 30,000 per QALY bar, leaving the EVH-dominant population as the real differentiation...

@moatrx • one week ago • comments: 0

Posted a new blog:
GERMANY PNH LAUNCH READINESS

Iptacopan cleared Germany's AMNOG via an orphan-drug shortcut; crovalimab, without that status, must win the same substantial-benefit finding directly. Iptacopan's...

@moatrx • one week ago • comments: 0

Posted a new blog:
GCC PNH LAUNCH READINESS

SFDA registration ahead of iptacopan, not differentiation from entrenched anti-C5 therapy, will decide GCC PNH launch success. Eculizumab and ravulizumab are...

@moatrx • one week ago • comments: 0

Posted a new blog:
FRANCE PNH LAUNCH READINESS

Iptacopan won French access via AP1 two weeks before its EU marketing authorization even took effect. France's Acces Precoce framework, reformed in 2021, runs two...

MoatRx